Anti-Hu associated paraneoplastic syndromes triggered...
Anti-Hu antibodies (Hu-Abs) are associated with diverse paraneoplastic neurological syndromes (PNS), usually in the context of small cell lung cancer (SCLC). Recently, the introduction of immune checkpoint inhibitors (ICIs) has led to a paradigm shift in oncology. Immune-related adverse events are, however, frequent, including neurological ones (nir-AEs). Interestingly, ICIs were able to trigger Yo-PNS in a murine model, and an increased frequency of Ma2-PNS was observed after ICI implementation in France. These reports raised concern as to the potential increase of Hu-PNS cases after ICI.
